The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (TRIOC)
A Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Sponsor: Cancer Research UK
This PHASE2 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently completed. Cancer Research UK leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Nov 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Research UK
- Oxford BioMedica
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .